Navigation Links
NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
Date:3/20/2008

ANN ARBOR, Mich., March 20 /PRNewswire/ -- NanoBio Corporation announced today that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists.

"Allowing adequate time for subjects to grow out a clear nail after successfully treating the infection will enable us to generate data on complete cure, the primary endpoint required by the FDA for approval of drugs to treat onychomycosis," said James R Baker Jr., M.D., founder and chairman of NanoBio Corporation.

The ongoing randomized, double-blind, vehicle-controlled study involving 443 subjects is being conducted at 22 sites in the United States and Canada. The interim analysis was performed on the first 160 subjects from the trial to complete the 24 week assessment of clear nail growth. Final results will be available in the first quarter of 2009.

The analysis confirmed the outstanding safety profile of NB-002 seen in previous human and animal trials, Baker said. Results from a phase 1 study in onychomycosis, as well as preclinical data, indicated that the product can be safely applied to the skin at doses more than 1,000 times higher than the minimum concentration required to kill fungi. In total, over 900 subjects have been treated with the NB-002 formulation without significant skin irritation, systemic absorption, or other safety concerns.

"NB-002 exerts its effect locally by penetrating to reach the nail bed where dermatophytes responsible for onychomycosis reside. It then kills both active hyphae and spores, without irritating the epithelium or being systemically absorbed," Baker said.

"The absence of systemic absorption provides a significant advance for onychomycosis therapy in terms of safety. Current oral (systemic) drugs for onychomycosis pose risks of hepatic and card
'/>"/>

SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
2. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
3. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
4. Synbiotics Corporation Announces Human Submission for FluDetect(R)
5. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
6. CEL-SCI Corporation Reports First Quarter Financial Results
7. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
8. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
11. CEL-SCI Corporation Announces 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... -- Rhythm announced today the presentation of results from a ... symptoms among diabetic patients in the U.S. than previously ... with both type 1 and type 2 diabetes, but ... more common type 2 disease. ... of Medicine at Harvard Medical School and Director of ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
... This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic ... European industry experts at Pharma IQ,s to discuss FDA ... Over the last two years, the regulations have been ... there has been some confusion within the industry as ...
... 2011 Morphotek®, Inc., a subsidiary of Eisai ... assets relating to a proprietary tumor targeting platform ... payment and future development milestones. TMI, a biotechnology ... the tumor-targeting peptide (TTP) platform capable of delivering ...
Cached Medicine Technology:FDA to Address Industry Questions About Biosimilar Regulations at the Pharma's IQ Immunogenicity Event 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:5/20/2013)... Lansing, MI (PRWEB) May 20, ... Michigan Lupus Foundation will be ... meeting in Lansing on June ... Monday, June 10th, 6:30 p.m. ... Professional Building (Across from Sparrow ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Co-founder of ... will be a keynote speaker at the 5th International ... The conference brings together company representatives and independent ... trends in Internet marketing and investments. , The 2013 ... Inn Business Hotel México from May 20 to 21. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 The ... and community leaders behind bars for good at an ... 22 beginning at 9 a.m. , More than ... Executive Lock-Up to benefit individuals and families affected by ... including city officials, local celebrities, realtors, doctors, attorneys, bankers, ...
(Date:5/20/2013)... May 20, 2013 ... Who:    Sloan Gibson, President, USO and CEO ... of Outreach Initiatives and Partners, Sesame ... , Representatives from:,              ... • U.S. House ...
(Date:5/20/2013)... 20, 2013 National law firm Parker Waichman ... Law Firm P.A., both based in Little Rock, Arkansas – ... proposed $7.25 billion settlement of a price-fixing case against Visa ... was filed Wednesday, May 15, 2013, in the U.S. District ... lawsuit against Visa and MasterCard (Case No. 1:05-md-1720) is titled ...
Breaking Medicine News(10 mins):Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 2Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 3
... in the open access journal BMC Medicine has found that ... people in India are flawed and the actual number of ... who are from the Administrative Staff College of India, conducted ... of Medical Sciences in Hyderabad. ,According to ...
... to be merry, for Christmas is fast approaching. The Santa ... celebration, spreading cheer// all around, are observed to be grossly ... ,Doctors in Scotland have explained how most of the ... frightfully fat, and need to diet on a war footing. ...
... spiritual leader Sri Sri Ravi Shankar will set up ... an "amalgamation of science and spirituality". ,Yezdi Batliwala ... Trust, the educational wing of the Art of Living ... Tripathy, the secretary of the state's higher education department, ...
... from Quebec had a man made heart implanted inside ... who does not have a heart beat! ,“Heartmate II”, ... Cecere and Dr Nadia Giannetti in a three-hour surgery on Nov. ... decade. It works using a turbine balanced within a magnetic field. ...
... most often end up selling their homes according to a ... ,People diagnosed with cancer experience loss of income, ... at the same time face a number of extra costs, ... ,The Macmillan Cancer Support research indicated that almost 20% ...
... problems are not protected from attacks or stroke by taking ... ,Folic acid or folate is one of the B ... Some medical practitioners prescribe it to prevent cardiac problems. ... Public Health and Tropical Medicine, New Orleans led a research ...
Cached Medicine News:
XL STABI Hydrophilic Acrylic Lens....
XL OCTO Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
MemoryLens Prefolded Acrylic Lens....
Medicine Products: